awmsg logo



galsulfase (Naglazyme®)


Reference No. 155

Publication date:
03/12/2013


Appraisal information

galsulfase (Naglazyme®) 1 mg/ml concentrate for solution for infusion


Company: BioMarin Europe Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, galsulfase (Naglazyme®) cannot be endorsed for use within NHS Wales for the treatment of long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome).
Statement of Advice (SOA)
Download